ViiV's Tivicay superior to Kaletra in Phase IIIb DAWNING trial for HIV-1 infection

In July, ViiV Healthcare Ltd. (Brentford, U.K.) said data from the Phase IIIb DAWNING trial to treat HIV-1 infection showed that a regimen containing Tivicay dolutegravir showed superior efficacy and had a favorable safety profile compared with a regimen including Kaletra lopinavir/ritonavir. An IDMC recommended discontinuation of the study's Kaletra arm based on differences in the rates of virologic non-response and increasing differences in virologic failure between

Read the full 673 word article

User Sign In